US4517303AExpiredUtility

Specific binding assays utilizing analyte-cytolysin conjugates

Assignee: DU PONTPriority: Oct 20, 1982Filed: Oct 20, 1982Granted: May 14, 1985
Est. expiryOct 20, 2002(expired)· nominal 20-yr term from priority
Y10S436/803Y10S436/829Y10S435/966Y10S436/813Y10S930/28Y10S436/827Y10S435/972G01N 33/586G01N 33/82Y10S436/817Y10S436/815G01N 33/53Y10S436/828G01N 33/554G01N 33/9453
82
PatentIndex Score
58
Cited by
16
References
40
Claims

Abstract

A novel analyte-cytolysin conjugate and its use in a lipid vesicle mediated measurement process is described for a wide variety of analytes present at very low concentration. The method involves forming a reaction system consisting of analyte, analyte specific binding agent, analyte-cytolysin conjugate, and vesicles containing detectable marker material in such proportions that uncombined conjugate alters the permeability of the vesicles resulting in the release and quantitative detection of marker material which can be correlated with the amount of analyte initially present.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A conjugate for the detection of an analyte in a test sample, comprising in combination: (1) cytolysin means for altering the permeability of a membrane of a vesicle, said means being conjugated to   (2) at least one analyte molecule.   
     
     
       2. The conjugate of claim 1 wherein the cytolysin is selected from the group consisting of aerolysin, amphotericin B, alamethicin, A-23187 (calcium ionophore), ATP translocase, cereolysin, diptheria toxin, filipin, gramicidin, melittin, nigericin, nystatin, polymyxin B, Staphylococcus aureus toxin α, β, γ, or δ, Streptolysin O, Streptolysin S, tubulin and valinomycin. 
     
     
       3. The conjugate of claim 1 wherein the cytolysin is melittin. 
     
     
       4. The conjugate of claim 3 wherein the attachment of analyte derivative is through an amino acid residue selected from the group consisting of lysine, serine, threonine, N-terminal glycine, and C-terminal glutamine. 
     
     
       5. The conjugate of claim 1 wherein the analyte derivative is a drug, metabolite, hormone, steroid, pesticide, environmental pollutant, food toxin, vitamin, protein, microbial surface marker, cancer cell marker, fungus, protozoan, virus, cell or tissue antigen. 
     
     
       6. The conjugate of claim 5 wherein the analyte derivative is a drug. 
     
     
       7. The conjugate of claim 6 wherein the drug is ouabain. 
     
     
       8. The conjugate of claim 4 wherein at least one ouabain molecule is attached to melittin through an ε-amino group of a lysine residue. 
     
     
       9. The conjugate of claim 5 wherein the analyte derivative is a vitamin. 
     
     
       10. The conjugate of claim 9 wherein the vitamin is biotin. 
     
     
       11. The conjugate of claim 4 wherein at least one biotin derivative molecule is attached to melittin through an ε-amino group of a lysine residue. 
     
     
       12. An analyte-cytolysin conjugate comprising a substituted melittin molecule of the formula: ##STR1## wherein at least one of R 1  through R 8  is an analyte derivative molecule selected from the group consisting of drug, vitamin, hormone, metabolite, steroid, pesticide, environmental pollutant, food toxin, protein, microbial surface marker, cancer cell marker, fungus, protozoan, cell or tissue antigen, provided that when at least one of R 2 , R 6 , or R 7  is said analyte derivative, attachment is through an ε-amino group of the amino acid side chain; when at least one of R 3 , R 4 , or R 5  is said analyte derivative, attachment is through a hydroxyl group of said amino acid side chain; when R 1  is said analyte derivative, attachment is through the N-terminal amino group; and when R 8  is said analyte derivative, attachment is through the C-terminal carboxyl group. 
     
     
       13. The conjugate of claim 12 wherein at least one of R 2 , R 6 , or R 7  is a ouabain derivative. 
     
     
       14. The conjugate of claim 12 wherein at least one of R 2 , R 6 , or R 7  is a biotin derivative. 
     
     
       15. A method for determining the amount of an analyte in liquid medium comprising the steps of: (A) forming a reaction system by contacting said liquid medium with (1) analyte specific binding agent;   (2) analyte-cytolysin conjugate; and   (3) vesicles containing marker material sequestered within the vesicle      in proportions such that the interaction of unbound analyte-cytolysin conjugate with said vesicles results in the release of said marker material; and   (B) measuring said marker material thereby released which is related to the amount of said analyte initially present in said liquid medium.   
     
     
       16. The method of claim 15 wherein the analyte is a drug, metabolite, hormone, steroid, pesticide, environmental pollutant, food toxin, vitamin, protein, microbial surface marker, cancer cell marker, fungus, protozoan, virus, cell or tissue antigen. 
     
     
       17. The method of claim 15 wherein the analyte is a drug. 
     
     
       18. The method of claim 17 wherein the drug is digoxin. 
     
     
       19. The method of claim 15 wherein the analyte is a vitamin. 
     
     
       20. The method of claim 19 wherein the vitamin is biotin. 
     
     
       21. The method of claim 15 wherein the analyte binding agent is selected from the group consisting of antibody, hormone-receptor, lectin, and specific binding protein. 
     
     
       22. The method of claim 21 wherein the binding agent is an antibody. 
     
     
       23. The method of claim 22 wherein the antibody is specific for digoxin. 
     
     
       24. The method of claim 21 wherein the binding agent is a specific binding protein. 
     
     
       25. The method of claim 24 wherein the specific binding protein is avidin. 
     
     
       26. The method of claim 15 wherein the analyte-cytolysin conjugate is ouabain-melittin. 
     
     
       27. The method of claim 15 wherein the analyte-cytolysin conjugate is biotin-melittin. 
     
     
       28. The method of claim 15 wherein the vesicle utilized to sequester marker material is selected from the group consisting of lipid vesicle, red blood cell, and red blood cell ghost. 
     
     
       29. The method of claim 28 wherein the vesicle is a lipid vesicle. 
     
     
       30. The method of claim 15 wherein the marker material is a substance selected from the group consisting of enzyme, cofactor, chromophore, fluorophore, spin label, and ion. 
     
     
       31. The method of claim 29 wherein the marker material is an enzyme. 
     
     
       32. The method of claim 30 wherein the enzyme is alkaline phosphatase. 
     
     
       33. The method of claim 30 wherein the enzyme is β-galactosidase. 
     
     
       34. The method of claim 30 wherein the fluorophore is 6-carboxyfluorescein. 
     
     
       35. A method for determining the amount of digoxin in liquid medium comprising the steps of: (A) forming a reaction system by contacting said liquid medium with (1) digoxin specific antibody;   (2) ouabain-melittin conjugate;   (3) lipid vesicles containing sequestered alkaline phosphatase; and   (4) p-nitrophenyl phosphate      in proportions such that the interaction of unbound ouabain-melittin conjugate and said lipid vesicles results in the conversion of said p-nitrophenyl phosphate by said alkaline phosphatase; and   (B) measuring the concentration of p-nitrophenlate anion produced which is related to the amount of said digoxin initially present in said liquid medium.   
     
     
       36. A conjugate for the detection of an analyte in a test sample, comprising in combination: (1) cytolysin means for altering the permeability of a membrane of a vesicle, said means being conjugaed to   (2) an antibody molecule capable of binding to the analyte.   
     
     
       37. The conjugate of claim 36 wherein the antibody molecule is a monovalent antibody molecule selected from the group consisting of Fab, Fab', and half-molecules. 
     
     
       38. The conjugate of claim 36 wherein the cytolysin is selected from the group consisting of aerolysin, amphotericin B, alamethicin, A-23187 (calcium ionophore), ATP translocase, cerolysin, diptheria toxin, filipin, gramicidin, melittin, nigericin, nystatin, polymyxin B, Staphylococcus aureus toxin α, β, γ, or δ, Streptolysin O, Streptolysin S, tubulin and valinomycin. 
     
     
       39. The conjugate of claim 8 wherein the cytolysin is mellitin. 
     
     
       40. A heterogeneous immunoassay for detecting an analyte in a liquid sample, comprising: (1) forming a reaction mixture by contacting the sample with a cytolysin/anti-analyte antibody conjugate in immunochemical excess over the analyte, whereby a fraction of said conjugate binds to analyte to form a complex and a fraction of said conjugate remains free,   (2) contacting the reaction mixture with a solid phase having analyte or analyte-analog bound thereto to separate the complex from the free conjugate, and   (3) contacting either the complex or the free conjugate with vesicles having marker material sequestered therein, whereby the permeability of the vesicle increases, thereby releasing marker material,   (4) measuring the amount of released marker material, and   (5) relating the amount of released marker material to the amount of analyte initially present in the test sample.

Join the waitlist — get patent alerts

Track US4517303A — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.